Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Conclusions</b>: Our data demonstrate that vitamin C kills thyroid cancer cells by inhibiting MAPK/ERK and PI3K/AKT pathways via a ROS-dependent mechanism and suggest that pharmaceutical concentration of vitamin C has potential clinical use in thyroid cancer therapy.
|
31285773 |
2019 |
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Purpose:</b> Targeting mutations leading to PI3K/mTOR/Akt activation are of interest in thyroid cancer.
|
29301825 |
2018 |
Thyroid carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Thyroid cancer is frequently associated to the activation of specific protein (RET, BRAF) and lipid [PI(3)K] kinases.
|
17891251 |
2007 |
Thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Thyroid cancer (TC) is frequently associated with BRAF or RAS oncogenic mutations and RET/PTC rearrangements, with aberrant RAF-MEK-ERK and/or PI3K pathway activation.
|
26265449 |
2015 |
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
PI3K inhibitors IC87114 inhibits the migration and invasion of thyroid cancer cell in vitro and in vivo.
|
29236327 |
2018 |
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
As in many other human cancers, overactivation of the phosphotidylinositol 3-kinase (PI3K)/Akt signaling pathway occurs frequently in thyroid cancer, but the mechanism is not completely clear.
|
15928251 |
2005 |
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
As phosphoinositide 3-kinase/protein kinase-B (PI3K/AKT) signaling is a fundamental oncogenic driver in many thyroid cancers, we explored a potential role for miR-146b and its target genes in PI3K/AKT activation.
|
29353884 |
2018 |
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
As the drivers of this process, many genetic alterations activating the PI3K/Akt pathway have been identified in thyroid cancer in recent years.
|
20578891 |
2010 |
Thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
c-Met-mediated reactivation of PI3K/AKT signaling contributes to insensitivity of BRAF(V600E) mutant thyroid cancer to BRAF inhibition.
|
26456083 |
2016 |
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CONCLUSIONS circ_0067934 could improve the development of thyroid carcinoma by promoting EMT and PI3K/AKT signaling pathways.
|
30779728 |
2019 |
Thyroid carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Demethylating the hypermethylated REC8 gene restored its expression in thyroid cancer cells in which the PI3K pathway was genetically over-activated and induced expression of REC8 protein inhibited the proliferation and colony formation of these cells.
|
26472282 |
2015 |
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, our data showed that the c-Met/PI3K/Akt signaling pathway was responsible for the inhibitory effect of ING5 on the thyroid cancer.
|
29272787 |
2018 |
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Genetic alterations in pathways, including the mitogen‑activated protein kinase (MAPK)/extracellular signal‑regulated kinase (Erk) and phosphatidylinositol‑3‑kinase (PI3K)/protein kinase B (Akt) pathways, are the driving force behind the development of differentiated thyroid cancer cases into aggressive and undifferentiated forms of thyroid cancer.
|
30365150 |
2019 |
Thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
GPCR-mediated PI3K pathway mutations in pediatric and adult thyroid cancer.
|
31289610 |
2019 |
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we identify Janus kinase/signal transducers and activators of transcription (STAT) and phosphatidyl inositol 3-kinase (PI3K)/AKT as the down-stream pathways through which these cytokines confer resistance to cell death in thyroid cancer.
|
19638576 |
2009 |
Thyroid carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
HIF-1 is functionally expressed in thyroid carcinomas and is regulated not only by hypoxia but also via growth factor signalling pathways and, in particular, the PI3K pathway.
|
19808899 |
2010 |
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, MAPK pathway is the predominant target for therapy in advance thyroid carcinomas; adding NGS enables the identification of comutations associated with resistance (<i>PI3K/AKT</i>).
|
29695638 |
2018 |
Thyroid carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, the data of this study suggested that naringin presented anti-tumor effects in TC cells through inhibiting TC cell proliferation and inducing cell apoptosis via regulating the expression of cell proliferation and apoptosis related genes and PI3K/AKT pathway activation.
|
31727500 |
2019 |
Thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In particular, SGK1 was found to be essential for proliferation and survival of thyroid cancer cells harboring PI3K-activating mutations.
|
29055016 |
2017 |
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this article, the role of PI3K pathway activation in thyroid cancer is discussed, with a focus on recent advances.
|
18502332 |
2008 |
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this review, we discuss the latest findings on the major components of the MAPK and PI3K pathways, including their mechanisms of activation in physiological and pathological contexts, their genetic alterations with respect to the different types of thyroid carcinomas and the more relevant drugs designed to block their activity.
|
28838947 |
2017 |
Thyroid carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Initiation and progression of thyroid cancer involves multiple genetic and epigenetic alterations, of which mutations leading to the activation of the MAPK and PI3K-AKT signaling pathways are crucial.
|
21878896 |
2011 |
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Long Noncoding RNA LINC003121 Inhibits Proliferation and Invasion of Thyroid Cancer Cells by Suppression of the Phosphatidylinositol-3-Kinase (PI3K)/Akt Signaling Pathway.
|
29969438 |
2018 |
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mechanically, our data demonstrated that tumor-promoting role of N-cadherin in thyroid cancer was closely related to the activities of the MAPK/Erk, the phosphatidylinositol-3-kinase (PI3K)/Akt and p16/Rb signaling pathways in addition to affecting the EMT process.
|
28042956 |
2017 |
Thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Metallothionein 1G functions as a tumor suppressor in thyroid cancer through modulating the PI3K/Akt signaling pathway.
|
24098937 |
2013 |